Friday December 05 2008 | Biotechnology feed | All feeds
|
|
Friday December 05 2008 | Biotechnology feed | All feeds
|
|
|
Best of Biotechnology on Show in Brisbane
Biotechnology companies continue to develop
leading-edge technologies to benefit human and animal health and the
environment. What are these innovations and what strategies are in place to
commercialise them?
The Business Partnering and Investment Forum
to be held during AusBiotech 2004 will provide Australian and international
companies the opportunity to showcase their technology and 'pitch' to
potential investors, partners, analysts and licensees to sign that ultimate
deal.
Case studies and pitches can be heard from Australian,
US, UK, NZ, Russian and Taiwan companies covering areas of human
therapeutics, platform technologies, agribusiness and natural products,
vaccine and infectious diseases.
Company pitches will include:
*Adipogen *Amgen
*Antisoma
Research Ltd, UK *Avexa
*BioDiem *Bionomics
*Biosignal
*Biovite Australia
*Cerylid
Bioscience *ChemGenex
Pharmaceuticals
*Coridon
*Cryptome Pharmaceuticals
*Cytopia *Dairy
CRC
*EQiTX
*EvoGenix
*Genvax *
Industrial Research Ltd, NZ
*Marinus
Pharmaceuticals Inc., USA *Minomic
*NuPlant *Ozmicrofluids
*Phylogica *Radical
Biotechnology
*Russian
Biotechnologies *Solbec
Pharmaceuticals
*Thrombostat
*Vaxien
*VaxTx
These technologies will also be on show in the
Exhibition Hall at Brisbane Convention & Exhibition Centre.
DIARY NOTE:
Media information:
Paris Brooke, Communication Manager, mob: 0407 715
574
Suzana Trajanovska, Communication Officer, mob:
0414 464 495
About AusBiotech Ltd
AusBiotech is Australia's Biotechnology Industry
Organisation, which represents over 2,400 Members, covering the human health,
agricultural, medical device, environmental and industrial sectors in
biotechnology. Our Membership base covers biotechnology companies, ranging
from start-ups to mature multinationals, research institutes and universities,
specialist service professionals, individual and student Members from
Australia and globally.
The information in this email and in any
attachments is confidential and may be privileged. If you are not the intended
recipient, please destroy this message, delete any copies held on your systems
and notify the sender immediately. You should not retain, copy or use this
email for any purpose, nor disclose all or any part of its content to any
other person.
|
|
|
